​Lilly Goes On Blitz: Slaps Copycat Weight-Loss Drug Makers With Cease & Desist Letters – Tyler Durden

Lilly Goes On Blitz: Slaps Copycat Weight-Loss Drug Makers With Cease & Desist Letters Eli Lilly has launched a wave of cease-and-desist orders targeting compounding pharmacies, telehealth companies, and medical spas that produce and sell “compounded” versions of tirzepatide, the active ingredient in the pharma giant’s diabetes drug Mounjaro and weight-loss wonder drug Zepbound.  As early as December 2022, Tirzepatide was placed on the Food and Drug Administration’s shortage list. The shortage designation allowed pharmacists, doctors, and licensed outsourcing facilities to compound copycats of Zepbound amid the GLP-1 craze that swept across America. It was removed from the list last Wednesday.…  — Continue at ZeroHedge News : Read More